Solid Biosciences - SLDB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.17
  • Forecasted Upside: 107.26%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$7.80
▼ -1.11 (-12.46%)

This chart shows the closing price for SLDB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Solid Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLDB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLDB

Analyst Price Target is $16.17
▲ +107.26% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $16.17, with a high forecast of $20.00 and a low forecast of $12.00. The average price target represents a 107.26% upside from the last price of $7.80.

This chart shows the closing price for SLDB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Solid Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2024

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$10.00 ➝ $15.00Low
6/24/2024Leerink PartnrsUpgradeHold ➝ Strong-BuyLow
6/24/2024SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00 ➝ $12.00Low
6/21/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$20.00 ➝ $20.00Low
5/31/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$12.00 ➝ $10.00Low
5/31/2024Piper SandlerInitiated CoverageOverweight$20.00Low
5/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00Low
5/16/2024BarclaysLower TargetOverweight ➝ Overweight$21.00 ➝ $18.00Low
3/28/2024William BlairReiterated RatingOutperformLow
3/18/2024BarclaysBoost TargetOverweight ➝ Overweight$8.00 ➝ $21.00Low
3/15/2024CitigroupInitiated CoverageBuy$16.00Low
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00Low
3/14/2024Piper SandlerUpgradeNeutral ➝ Overweight$8.00 ➝ $20.00Low
12/8/2023HC WainwrightInitiated CoverageBuy$9.00Low
9/22/2023Cantor FitzgeraldInitiated CoverageOverweightLow
10/17/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$180.00 ➝ $15.00Low
9/30/2022JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
8/12/2022Chardan CapitalLower TargetBuy$105.00 ➝ $90.00Low
5/18/2022Piper SandlerLower TargetNeutral$75.00 ➝ $30.00Low
4/28/2022Chardan CapitalLower Target$255.00 ➝ $105.00High
4/27/2022SVB LeerinkReiterated RatingOutperformHigh
4/27/2022Piper SandlerLower Target$90.00 ➝ $75.00High
9/24/2021Chardan CapitalLower TargetBuy$300.00 ➝ $255.00High
7/12/2021Piper SandlerInitiated CoverageNeutral$90.00High
7/1/2021Chardan CapitalReiterated RatingBuyHigh
5/27/2021Jefferies Financial GroupInitiated CoverageBuy$105.00High
5/17/2021BarclaysLower TargetOverweight$195.00 ➝ $120.00Medium
3/16/2021Chardan CapitalBoost TargetBuy$187.50 ➝ $300.00High
3/16/2021Credit Suisse GroupBoost TargetNeutral$105.00 ➝ $120.00High
3/16/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$45.00 ➝ $225.00High
3/14/2021SVB LeerinkReiterated RatingHold$45.00Low
3/9/2021BarclaysInitiated CoverageOverweight$195.00High
1/8/2021Chardan CapitalReiterated RatingBuy$187.50High
1/8/2021Credit Suisse GroupUpgradeUnderperform ➝ Neutral$30.00 ➝ $105.00High
10/1/2020Chardan CapitalBoost TargetBuy$75.00 ➝ $187.50High
8/14/2020Chardan CapitalReiterated RatingBuy$75.00Medium
7/27/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$45.00High
5/21/2020NomuraReiterated RatingBuy$90.00Low
5/9/2020Chardan CapitalReiterated RatingBuy$75.00High
5/8/2020NomuraLower TargetBuy$150.00 ➝ $90.00Low
3/23/2020Chardan CapitalReiterated RatingBuy$101.25 ➝ $75.00High
12/18/2019Nomura SecuritiesBoost TargetBuy$90.00 ➝ $150.00High
11/12/2019Credit Suisse GroupLower TargetUnderperform ➝ Hold$90.00 ➝ $30.00High
10/11/2019Evercore ISIInitiated CoverageOutperform$330.00High
8/29/2019CitigroupDowngradeNeutral ➝ Sell$90.00High
8/19/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$120.00 ➝ $225.00High
8/16/2019Chardan CapitalUpgradeNeutral ➝ Buy$112.50 ➝ $150.00High
(Data available from 7/19/2019 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/20/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/21/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/19/2024

Current Sentiment

  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Solid Biosciences logo
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Read More

Today's Range

Now: $7.80
Low: $7.80
High: $9.14

50 Day Range

MA: $7.65
Low: $5.67
High: $10.39

52 Week Range

Now: $7.80
Low: $1.81
High: $15.05

Volume

296,040 shs

Average Volume

985,716 shs

Market Capitalization

$299.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Solid Biosciences?

The following sell-side analysts have issued research reports on Solid Biosciences in the last twelve months: Barclays PLC, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Leerink Partnrs, Piper Sandler, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for SLDB.

What is the current price target for Solid Biosciences?

6 Wall Street analysts have set twelve-month price targets for Solid Biosciences in the last year. Their average twelve-month price target is $16.17, suggesting a possible upside of 107.3%. Piper Sandler has the highest price target set, predicting SLDB will reach $20.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $12.00 for Solid Biosciences in the next year.
View the latest price targets for SLDB.

What is the current consensus analyst rating for Solid Biosciences?

Solid Biosciences currently has 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLDB will outperform the market and that investors should add to their positions of Solid Biosciences.
View the latest ratings for SLDB.

What other companies compete with Solid Biosciences?

How do I contact Solid Biosciences' investor relations team?

Solid Biosciences' physical mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 337-4680 and its investor relations email address is [email protected]. The official website for Solid Biosciences is www.solidbio.com. Learn More about contacing Solid Biosciences investor relations.